Adrenal disease

Long-term clinical outcomes of primary adrenal insufficiency caused by homozygous CYP11A1 p.R451W variant

Eur J EndocrinolPublished Retrospective cohort study

Authors' conclusion

Mild P450scc deficiency due to p.R451W variant in the CYP11A1 gene is associated with late onset PAI with variable MC and sex hormone deficiency. The growth is consistent with genetic potential, and pubertal onset and progression are normal in affected patients, while long-term follow-up is required with regard to the risk of gonadal failure.

Study context

Population
Patients with homozygous CYP11A1 c.1351C > T (p.R451W) variant (mild P450scc deficiency), tertiary pediatric endocrinology centers16 males · 16 families
Participants
22 patients
Outcome
Long-term growth, pubertal development, and adrenal and gonadal functions
Methodological detailsmulticentre, tertiary pediatric endocrinology centers
  • Multicentre
  • Tertiary pediatric endocrinology centers

Main finding

As reported in the abstract

mean follow-up 7.8 ± 5.2 years (range: 0.5-17.9 years)
Primary adrenal insufficiency (PAI) present in all cases
22
Mineralocorticoid (MC) deficiency detected
20 patients (83%)
MC deficiency recovered during follow-up
2 cases
Salt-wasting crisis during acute illness in patient with no MC deficiency at presentation
1 patient
Atypical genitalia in 46,XY cases
0
Micropenis (46,XY)
3
Cryptorchidism (46,XY)
1
Required sex steroid therapy for subsequent hypergonadotropic hypogonadism
2 patients

Observational data: associations, not effects.

Further findings

Age at presentation

Median age at presentation 4.8 ± 4.2 years (range: 1-14.6 years)

Diagnosis during family screening

Diagnosed during family screening
3 patients

Original publication

Long-term clinical outcomes of primary adrenal insufficiency caused by homozygous CYP11A1 p.R451W variant. Eur J Endocrinol. Published 24 June 2026. doi:10.1093/ejendo/lvag110

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.